Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective reduced by HC Wainwright from $27.00 to $18.00 in ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer ...

H.C. Wainwright lowered the firm’s price target on Enanta (ENTA) to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully ...

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

Enanta Pharmaceuticals (ENTA) announced that the United States District Court of Massachusetts has issued a ruling on a summary judgment motion ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the ...